baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

IDORSIA AG SF-,05/ CH0363463438 /

04/06/2024 14:58:27	Chg. -0.146	Volume	Bid14:58:27	Ask14:58:27	Market Capitalization	Dividend Y.	P/E Ratio
2.524EUR	-5.47%	- Turnover: -	2.524Bid Size: -	2.556Ask Size: -	-EUR	-	-

GlobeNewswire 28/02 Idorsia and Viatris enter into a significant global research and development collaboration

GlobeNewswire 03/11/2023 New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at th...

GlobeNewswire 08/02/2022 Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profit...

GlobeNewswire 26/01/2022 Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and ...

GlobeNewswire 10/01/2022 Idorsia presents at the 40th J.P. Morgan Healthcare Conference – Ready for first product launches – ...

GlobeNewswire 10/01/2022 Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults ...

GlobeNewswire 27/07/2021 Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a f...

GlobeNewswire 20/07/2021 Invitation to Idorsia's half year financial results 2021 webcast and conference call

GlobeNewswire 28/06/2021 Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardi...

GlobeNewswire 09/06/2021 Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021

GlobeNewswire 22/04/2021 Idorsia announces financial results for the first quarter 2021 – substantial progress made across th...

GlobeNewswire 10/03/2021 FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult...

GlobeNewswire 01/03/2021 Idorsia submits NDA for clazosentan to Japanese PMDA

GlobeNewswire 11/01/2021 Idorsia to debut at the 39th J.P. Morgan Healthcare Conference – Major catalysts expected in the nea...

GlobeNewswire 23/11/2020 Idorsia announces positive results of the two Japanese registration studies with clazosentan

GlobeNewswire 02/09/2020 Janssen announces the presentation of additional ponesimod data at MSVirtual2020: 8th Joint ACTRIMS-...

GlobeNewswire 31/08/2020 Idorsia selects Syneos Health as commercialization partner to launch daridorexant in the United Stat...

GlobeNewswire 28/08/2020 Daridorexant Phase 3 results in insomnia presented at SLEEP 2020

GlobeNewswire 13/08/2020 Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020

GlobeNewswire 23/07/2020 Idorsia announces financial results for the first half 2020

GlobeNewswire 16/07/2020 Idorsia establishes US commercial operations and leadership team

GlobeNewswire 06/07/2020 Idorsia announces positive results in the second Phase 3 study of daridorexant

GlobeNewswire 03/05/2019 Idorsia holds its second Annual General Meeting of Shareholders - All Board proposals approved

GlobeNewswire 18/04/2019 Idorsia announces financial results for the first quarter 2019

GlobeNewswire 29/03/2019 Idorsia issues invitation to 2019 Annual General Meeting of Shareholders

IDORSIA AG SF-,05/ CH0363463438 /

If you wish to receive reply to your feedback, please provide your email address.